Fate Therapeutics shares are trading higher. The company announced data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. FATE | 0.00 |
Fate Therapeutics shares are trading higher. The company announced data from its off-the-shelf CAR T-cell programs will be featured at the American Society of Cancer Oncology Annual Meeting
